skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8838

Atherogenic dyslipidemia and diabetes mellitus: what’s new in the management arena?

Review

(2947) Views  (982) Full article downloads

Authors: Ajoy Kumar, Vibhuti Singh

Published Date July 2010 Volume 2010:6 Pages 665 - 669
DOI: http://dx.doi.org/10.2147/VHRM.S5686

Ajoy Kumar1, Vibhuti Singh2

1Bayfront Family Medicine Residency, St Petersburg FL, USA; 2University of South Florida College of Medicine and Suncoast Cardiovascular Center, St Petersburg, FL, USA

Abstract: When compared with the general population, the diabetic population is at higher risk of cardiovascular disease (CVD), as predicted by the Framingham Risk Score calculations (10-year risk 20%). For this reason diabetes is considered a “coronary disease equivalent” condition, as classified by the National Cholesterol Education Program Adult Treatment Panel (NCEP-ATP) III. Furthermore, patients with diabetes who experience a myocar­dial infarction have a poorer prognosis than non­diabetic patients, which contributes to their overall higher mortality. Dyslipidemia is a major underlying risk factor contributing to the excess CVD risk, and is usually more atherogenic in the presence of diabetes. It is uniquely manifested by raised levels of triglycer­ides, low levels of high-density lipoprotein cholesterol, and smaller, denser, and more atherogenic low-density lipoprotein particles. Recent trials have suggested the need for more aggressive treatment of dyslipidemia in this subpopulation than the current recommendations by the NCEP-ATP III. This review addresses the newer developments in the diabetes arena in terms of our current understanding of atherogenic dyslipidemia in diabetes and data from the latest randomized trials addressing its management.

Keywords: atherogenic dyslipidemia, diabetes mellitus







Readers of this article also read:

The management of gestational diabetes
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Practical recommendations for treatment of hypertension in older patients
Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid
Weight neutrality with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and clinical experience
The utility of troponin measurement to detect myocardial infarction: review of the current findings
Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: a systematic review
Low high-density lipoprotein cholesterol: current status and future strategies for management
Effect of vascular burden as measured by vascular indexes upon vascular dementia: a matched case-control study
Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy?
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University